Current issue
About the Journal
Scientific Council
Editorial Board
Regulatory and archival policy
Code of publishing ethics
Publisher
Information about the processing of personal data in relation to cookies and newsletter subscription
Archive
For Authors
For Reviewers
Contact
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Links
Sklep Wydawnictwa SUM
Biblioteka Główna SUM
Śląski Uniwersytet Medyczny w Katowicach
Privacy policy
Accessibility statement
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Effect of treating morbid obesity by intragastric balloon implantation on patients’ multimorbidity
1
Department of Epidemiology and Biostatistics, School of Health Sciences in Bytom, Medical University of Silesia in Katowice, Poland
2
Department of Emergency Medicine, School of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland
Corresponding author
Karolina Helena Krupa-Kotara
Zakład Epidemiologii, Katedra Epidemiologii i Biostatystyki, Wydział Nauk o Zdrowiu w Bytomiu, Śląski Uniwersytet Medyczny w Katowicach, ul. Piekarska 18, 41-902 Bytom
Zakład Epidemiologii, Katedra Epidemiologii i Biostatystyki, Wydział Nauk o Zdrowiu w Bytomiu, Śląski Uniwersytet Medyczny w Katowicach, ul. Piekarska 18, 41-902 Bytom
Ann. Acad. Med. Siles. 2020;74:157-165
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Morbid obesity and its accompanying multimorbidity constitute a significant public health problem.
Aim:
The aim of the study is to evaluate the effect of endoscopic implantation of an intragastric balloon on the ailments and associated diseases in people with obesity.
Material and methods:
The study included 75 people treated by intragastric balloon implantation. The sample selection was purposeful. The patients were qualified for balloon implantation, according to recognized indications for the endoscopic treatment of obesity. All the analyses were performed using Statistica 12. Results for which p < 0.05 were considered as statistically significant.
Results:
Positive effects of the treatment of obesity by intragastric balloon implantation in relation to comorbidities were observed in 54 patients (62%), 30 people (40%) achieved minimal health improvement, the regression of one serious disease and alleviation others in 24 patients (32%). 21 patients (28%) had no improvement in their health status. None of the patients reported the resolution of all major diseases, but there was also no deterioration in the health of any patient. There was a statistically significant reduction in the incidence of hypertension, type 2 diabetes, spinal pain, osteoarthritis, sleep apnoea, menstrual disorders, impotence and dyspnoea during IGB treatment
Conclusions:
Treatment by endoscopic implantation of an intragastric balloon alleviates the course or reduces the incidence of concomitant diseases in persons with morbid obesity.
Morbid obesity and its accompanying multimorbidity constitute a significant public health problem.
Aim:
The aim of the study is to evaluate the effect of endoscopic implantation of an intragastric balloon on the ailments and associated diseases in people with obesity.
Material and methods:
The study included 75 people treated by intragastric balloon implantation. The sample selection was purposeful. The patients were qualified for balloon implantation, according to recognized indications for the endoscopic treatment of obesity. All the analyses were performed using Statistica 12. Results for which p < 0.05 were considered as statistically significant.
Results:
Positive effects of the treatment of obesity by intragastric balloon implantation in relation to comorbidities were observed in 54 patients (62%), 30 people (40%) achieved minimal health improvement, the regression of one serious disease and alleviation others in 24 patients (32%). 21 patients (28%) had no improvement in their health status. None of the patients reported the resolution of all major diseases, but there was also no deterioration in the health of any patient. There was a statistically significant reduction in the incidence of hypertension, type 2 diabetes, spinal pain, osteoarthritis, sleep apnoea, menstrual disorders, impotence and dyspnoea during IGB treatment
Conclusions:
Treatment by endoscopic implantation of an intragastric balloon alleviates the course or reduces the incidence of concomitant diseases in persons with morbid obesity.
REFERENCES (40)
2.
World Health Organization. Global health risks: mortality and burden of di-sease attributable to selected major risks. Geneva; 2009: 9−31.
3.
World Health Organization. Obesity and overweight. Facts sheet N°311; 2015 [Dostęp: 4.05.2017].
4.
Finkelstein E.A., Khavjou O.A., Thompson H., Trogdon J.G., Pan L., Sherry B., Dietz W. Obesity and severe obesity forecasts through 2030. Am. J. Prev. Med. 2012; 42: 563−570, doi: 10.1016/j.amepre.2011.10.026.
5.
Stanowski E., Wyleżoł M., Paśnik K. Laparoskopia w chirurgii bariatrycznej w Polsce – stan aktualny. Wideochir. Inne Tech. Maloinwazyjne 2007: 2(1): 18−23.
6.
Sjöström L., Narbro K., Sjöström C.D., Karason K., Larsson B., Wedel H., Lystig T., Sullivan M., Bouchard C., Carlsson B., Bengtsson C. et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 2007; 357(8): 741−752, doi: 10.1056/NEJMoa066254.
7.
Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J. Intern. Med. 2013; 273(3): 219−234, doi: 10.1111/joim.12012.
8.
Wylezol M.S., Zwirska-Korczala K., Pasnik K. Bariatric surgery in Poland from 1993 to 2003. J. Physiol. Pharmacol. 2005; 56(6): 109−115.
9.
Abell T.L., Minocha A. Gastrointerstinal complications of bariatric surgery: diagnosis and therapy. Am. J. Med. Sci. 2006; 331(4): 214−218, doi: 10.1097/00000441-200604000-00008.
10.
Hu B., Chug S.C.S., Sun L.C.L., Kawashima K., Yamamoto T., Cotton P.B., Gostout C.J., Hawes R.H., Kalloo A.N., Kantsevoy S.V., Pasricha P.J. Transoral obesity surgery: Endoluminal gastroplasty with an endoscopic suture device. Endoscopy 2005; 37(5): 411−414, doi: 10.1055/s-2005-861196.
11.
Żurawiński W., Sosada K., Jopek J., Piecuch J., Mazur I. Endoskopowe leczenie otyłości z zastosowaniem balonu dożołądkowego. Pol. Przegl. Chir. 2010; 82(7): 754−761.
12.
Buchwald H., Oien D.M. Metabolic/bariatric surgery worldwide 2011. Obes. Surg. 2013; 23(4): 427−436, doi: 10.1007/s11695-012-0864-0.
13.
Dumonceau J.M. Evidence-based review of the bioenterics intragastric balloon for weight loss. Obes. Surg. 2008; 18(12): 1611−1617, doi: 10.1007/s11695-008-9593-9.
14.
Fred M., Hainer W., Basdevant A. et al. Interdisciplinary European guidelines on surgery of severe obesity. Obesity Facts 2008; 1: 52–59, doi: 10.1159/000113937.
15.
Oria H.E., Moorehead M.K. Bariatric analysis and reporting outcome system (BAROS) Obes. Surg. 1998; 8(5): 487−499, doi: 10.1381/096089298765554043.
16.
Wallace E., Salisbury C., Guthrie B., Lewis C., Fahey T., Smith S.M. Managing patients with multimorbidity in primary care. BMJ 2015; 350: h176, doi: 10.1136/bmj.h176.
17.
Jędrzejuk D., Milewicz A. Nadwaga i otyłość. [W:] Choroby serca i naczyń. Poradnik lekarza rodzinnego. Red. G. Opolski, W. Lukas, A. Steciwko. Via Medica. Gdańsk 2007; 5161.
18.
Chen Z.A., Roy K., Gotway Crawford C. Obesity prevention: the impact of local health departments. Health Serv. Res. 2013; 48(2 Pt 1): 603−627, doi: 10.1111/j.1475-6773.2012.01447.x.
19.
Buksińska-Lisik M., Lisik W., Zaleska T. Otyłość − choroba interdyscyplinarna. Przew. Lek. 2006; 9(1): 72−77.
20.
Karam J., McFarlane S. Tackling obesity: new therapeutic agents for assisted weight loss. Diabetes. Metab. Syndr. Obes. 2010; 3: 95−112.
21.
Doldi S.B., Micheletto G., Di Prisco F., Zappa M.A., Lattuada E., Reitano M. Intragastric balloon in obese patients. Obes. Surg. 2000; 10: 578−581, doi: 10.1381/096089200321594200.
22.
Żurawiński W., Sokołowski D., Krupa-Kotara K., Czech E., Sosada K. Evaluation of the results of treatment of morbid obesity by the endoscopic intragastric balloon implantation method. Wideochir. Inne Tech. Maloinwazyjne 2017; 12(1): 37−48, doi: 10.5114/wiitm.2017.66856.
23.
Genco A., Bruni T., Doldi S., Forestieri P., Marino M., Busetto L., Giardiello C., Angrisani L., Pecchioli L., Stornelli P., Puglisi F. et al. Bioenterics intragastric balloon: The Italian experience with 2 515 Patients. Obes. Surg. 2005; 15(8): 1161−1164, doi: 10.1381/0960892055002202.
24.
Mui W.L., Ng E.K., Tsung B.Y., Lam C.H., Yung M.Y. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes. Surg. 2010; 20(8): 1128−1132, doi: 10.1007/s11695-008-9766-6.
25.
Mitura K., Garnysz K. Tolerance of intragastric balloon and patient’s sa-tisfaction in obesity treatment. Wideochir. Inne Tech. Maloinwazyjne 2015; 10(3): 445−449, doi: 10.5114/wiitm.2015.54047.
26.
Mathus-Vliegen E.M., Tytgat G.N., Veldhuyzen-Offermans E.A. Intragastric balloon in the treatment of super-morbid obesity. Double-blind, sham-controlled, crossover evaluation of 500-milliliter balloon. Gastroenterology 1990; 99(2): 362−369, doi: 10.1016/0016-5085(90)91017-z.
27.
Mathus-Vliegen E.M.H. Efficacy of bioenterics intragastric balloon treatment in a prospective 2 years follow-up study. Presented at the Eighth European Congress on Obesity; 1997 Aug. Dublin, Ireland: European Congress on Obesity, 1997.
28.
Göttig S., Daskalakis M., Weiner S., Weiner R.A. Analysis of safety and efficacy of intragastric balloon in extremely obese patients. Obes. Surg. 2009; 19(6): 677−683, doi: 10.1007/s11695-009-9820-z.
29.
Al Kahtani K., Qaseem Khan M.Q., Helmy A., Al Ashgar H., Rezeig M., Al Quaiz M., Kagevi I., Al Sofayan M., Al Fadda M. Bio-enteric intragastric balloon in obese patients: A retrospective analysis of King Faisal Specialist Hospital Experience. Obes. Surg. 2010; 20: 1219−1226, doi: 10.1007/s11695-008-9654-0.
30.
Dastis S.N., François E., Deviere J., Hittelet A., Ilah Mehdi I.A., Barea M., Dumonceau J.M. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy 2009; 41(7): 575−580, doi: 10.1055/s-0029-1214826.
31.
Peker Y., Coskun H., Bozkurt S., Cin N., Atak T., Gencdoi H. Comparison of results of laparoscopic gastric banding and consecutive intragastric balloon application at 18 months: a clinical prospective study. J. Laparoendosc. Adv. Surg. Tech. A 2011; 21(6): 471−475, doi: 10.1089/lap.2010.0439.
32.
Genco A., López-Nava G., Wahlen C., Maselli R., Cipriano M., Mara Arenas Sanchez M., Jacobs C., Lorenzo M. Multi-centre European expe-rience with intragastric balloon in overweight populations: 13 years of experience. Obes. Surg. 2013; 23(4): 515−521, doi: 10.1007/s11695-012-0829-3.
33.
Zheng Y., Wang M., He S., Ji G. Short‑term effects of intragastric balloon in association with conservative therapy on weight loss: a meta‑analysis. J. Transl. Med. 2015; 13: 246, doi: 10.1186/s12967-015-0607-9.
34.
Evans J.D., Scott M.H. Intragastric balloon in the treatment of patients with morbid obesity. Br. J. Surg. 2001; 88(9): 1245−1248, doi: 10.1046/j.0007-1323.2001.01840.x.
35.
Pretolesi F., Redaelli G., Papagni L., Derchi L.E. Intragastric balloon for morbid obesity causing chronic gastric dilatation. Eur. Radiol. 2001; 11(4): 588−589, doi: 10.1007/s003300000629.
36.
Mathus-Vliegen E.M., Tytgat G.N. Intragastric balloon for treatment-resi-stant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc 2005; 61(1): 19−27, doi: 10.1016/s0016-5107(04)02406-x.
37.
Nijhof H.W., Steenvoorde P., Tollenaar R.A. Perforation of the esophagus caused by the insertion of an intragastric balloon for the treatment of obesity. Obes. Surg. 2006; 16(5): 667−670, doi: 10.1381/096089206776944887.
38.
Giardiello C., Cristiano S., Cerbone M.R., Troiano E., Iodice G., Sarrantonio G. Gastric perforation in an obese patient with an intragastric balloon, following previous fundoplication. Obes. Surg. 2003; 13(4): 658−660, doi: 10.1381/096089203322190925.
39.
Ballare M., Orsello M., Del Piano M. A case of death after insertion of an intragastric balloon for treatment of morbid obesity. Dig. Liver Dis. 2004; 36(7): 499, doi: 10.1016/j.dld.2004.03.005.
40.
Koutelidakis I., Dragoumis D., Papaziogas B., Patsas A., Katsougianopoulos A., Atmatzidis S., Atmatzidis K. Gastric perforation and death after the insertion of an intragastric balloon. Obes. Surg. 2009; 19: 393−396, doi: 10.1007/s11695-008-9706-5.
| eISSN: | 1734-025X |
The Medical University of Silesia in Katowice, as the Operator of the annales.sum.edu.pl website, processes personal data collected when visiting the website. The function of obtaining information about Users and their behavior is carried out by voluntarily entered information in forms, saving cookies in end devices, as well as by collecting web server logs, which are in the possession of the website Operator. Data, including cookies, are used to provide services in accordance with the Privacy policy.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
